LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Replaces Surgery for Bowel Cancer Tumor Determination

By LabMedica International staff writers
Posted on 01 Apr 2015
Print article
Image: Histologic section of a colonic adenoma containing invasive carcinoma (Photo courtesy of Dr. Mauro Risio).
Image: Histologic section of a colonic adenoma containing invasive carcinoma (Photo courtesy of Dr. Mauro Risio).
A blood test has been developed that could spare patients the stress of having tissue removed via biopsies for cancer diagnosis and to make the targeted use of therapy easier.

An assessment has been made of patients with metastasized bowel cancer to determine whether it is possible to characterize tumor and better control resistance mechanisms with a diagnostic blood test.

Scientists at the Medical University of Vienna (Austria) are now commencing a study which involves patients with metastasized bowel cancer who are undergoing a new diagnostic method, namely liquid biopsy in the form of a blood test. The aim of this new method is to spot a tumor's development of resistance early on and therefore adjust the treatment quickly and in a targeted manner.

Liquid biopsies utilize the fact that tumors and their metastases excrete tumor cells and fragments of tumor DNA, which then circulate in the blood. Since blood samples are usually not stressful for patients, and they are also easier, faster and cheaper to carry out than tissue biopsies, the establishment of liquid biopsies as the standard method would represent a milestone in the diagnosis of progression and therefore treatment of metastasized bowel cancer. The new clinical study, which bears the name CRC-RELY (Colorectal Cancer Regorefanib Liquid Biopsy), is a multicenter project led by the Medical University of Vienna and is receiving active input from other hospitals in Austria, Italy, and Switzerland.

Gerald Prager, MD, a professor and specialist in internal medicine, said, “On treatment, tumors often change their biological characteristics. This allows them to develop resistance to the treatment being given. To detect these changes and in order to be able to respond to them with medications, regular samples of tumor tissue or biopsies would be needed. These are taken, for example, as part of small operations or during computerized tomography (CT) scans, however they are associated with a risk for the patient and they are stressful. With this clinical study, we are one of the first organizations worldwide to address the establishment of this diagnostic method.”

Related Links:

Medical University of Vienna 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more